tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fredericks S et al. | Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. | 2006 | Transplantation | pmid:16969296 |
| Ogunseinde BA et al. | A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant. | 2003 | Transplantation | pmid:12883222 |
| Gralla J and Wiseman AC | Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. | 2009 | Transplantation | pmid:19502965 |
| Alloway RR | Mounting Clinical Evidence With Tacrolimus Generic Products. | 2017 | Transplantation | pmid:28749820 |
| Shirakata Y et al. | Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. | 1995 | Transplantation | pmid:8545894 |
| Lee D et al. | Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. | 2017 | Transplantation | pmid:27779572 |
| Hostettler KE et al. | Cyclosporine A mediates fibroproliferation through epithelial cells. | 2004 | Transplantation | pmid:15223908 |
| Yang CW et al. | Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. | 2003 | Transplantation | pmid:12544865 |
| Lykavieris P et al. | Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. | 2003 | Transplantation | pmid:12544888 |
| Moffatt SD et al. | Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. | 1999 | Transplantation | pmid:10342309 |
| Guethoff S et al. | Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. | 2013 | Transplantation | pmid:23423270 |
| Naesens M et al. | The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. | 2007 | Transplantation | pmid:17700162 |
| Krentz AJ et al. | Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. | 1994 | Transplantation | pmid:7516590 |
| Huang E et al. | Alemtuzumab induction in deceased donor kidney transplantation. | 2007 | Transplantation | pmid:17984833 |
| Kato T et al. | Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. | 2007 | Transplantation | pmid:17984834 |
| Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
| Utsugi R et al. | Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully mhc-mismatched kidney allografts in miniature swine. | 2001 | Transplantation | pmid:11391221 |
| Krentz AJ | Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655. | 2001 | Transplantation | pmid:11726815 |
| Jeske HC et al. | Gemcitabine with cyclosporine or with tacrolimus exerts a synergistic effect and induces tolerance in the rat. | 2003 | Transplantation | pmid:14557751 |
| Muthukumar T et al. | HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. | 2013 | Transplantation | pmid:23503504 |
| Hricik DE et al. | Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2007 | Transplantation | pmid:17297401 |
| Thervet E et al. | Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. | 2003 | Transplantation | pmid:14578760 |
| Jain A et al. | Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. | 2000 | Transplantation | pmid:10972220 |
| Kaplan B et al. | Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. | 1996 | Transplantation | pmid:8900321 |
| Newell KA et al. | Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. | 1996 | Transplantation | pmid:8779685 |
| Textor SC et al. | Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. | 1993 | Transplantation | pmid:7685934 |
| Gruber SA et al. | Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. | 2000 | Transplantation | pmid:10933170 |
| Shapiro R et al. | Alopecia as a consequence of tacrolimus therapy. | 1998 | Transplantation | pmid:9603186 |
| Muraki T et al. | Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. | 1998 | Transplantation | pmid:9583878 |
| Fernandez LA et al. | The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. | 1999 | Transplantation | pmid:10589951 |
| Kadry Z et al. | Kaposi's sarcoma in liver transplant recipients on FK506. | 1998 | Transplantation | pmid:9583882 |
| Batten P et al. | Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro. | 1999 | Transplantation | pmid:10589954 |
| Kandula P et al. | Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. | 2012 | Transplantation | pmid:23037007 |
| Holt S and Moore K | Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. | 2002 | Transplantation | pmid:11907407 |
| Yang H et al. | Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. | 2002 | Transplantation | pmid:11907415 |
| St A Nunes FA and Lucey MR | Searching for a balance when applying immunosuppression after liver transplantation. | 2001 | Transplantation | pmid:11258425 |
| Vafadari R et al. | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 | Transplantation | pmid:22960764 |
| Opelz G and Döhler B | Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. | 2009 | Transplantation | pmid:19300179 |
| Apanay DC et al. | Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. | 1994 | Transplantation | pmid:7524202 |
| Steinmüller TM et al. | The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. | 1994 | Transplantation | pmid:7524203 |
| Thomas PG et al. | Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. | 2007 | Transplantation | pmid:17565326 |
| Roberti I et al. | Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. | 1992 | Transplantation | pmid:1384182 |
| Nankivell BJ et al. | Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. | 2004 | Transplantation | pmid:15167607 |
| Gibson SW et al. | Nutritional immunomodulation leads to enhanced allograft survival in combination with cyclosporine A and rapamycin, but not FK506. | 2000 | Transplantation | pmid:10852592 |
| Ciancio G et al. | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. | 2013 | Transplantation | pmid:23903014 |
| Lerut J et al. | Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. | 2005 | Transplantation | pmid:16314784 |
| Gruessner RW et al. | Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. | 2008 | Transplantation | pmid:18192910 |
| Komori K et al. | The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. | 2008 | Transplantation | pmid:18192920 |
| Meiser BM et al. | Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | 2004 | Transplantation | pmid:15446320 |
| Murase N et al. | Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. | 1993 | Transplantation | pmid:7678353 |